Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A 12-week study of GW876008 versus placebo and paroxetine in social anxiety disorder
2006-003597-10Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emicerfont in Social Anxiety Disorder (SAD) (4 arms), sponsored by GSK. Primary endpoint: Key Decision Making Endpoints. Started Sep 2006; status: completed.
02
Drugs
emicerfont
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on 2006-003597-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003597-10.